Female Sexual Dysfunction in Renal Failure

Female Sexual Dysfunctions in Patients With Chronic Renal Failure

A myriad of sexual problems affect men and women with chronic kidney disease (CKD), including decreased libido, erectile dysfunction, dysmenorrhea, and infertility. Menstrual abnormalities are common in CKD and many women are an-ovulatory .

Causes of sexual dysfunction in CKD include hormonal alterations along with vascular, neurologic, psychogenic, and other factors, such as medications, contribute to the development of sexual dysfunction . Sexual dysfunction in females is mainly due to hormonal factors and manifests mainly as menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive.

Study Overview

• Status: Unknown
• Conditions: Evaluations of Sexual Dysfunction of Female in Chronic Renal Failure

Detailed Description

Hormonal changes in chronic kidney disease are seen in prolactine, gonadotropins, and gonadal hormones. In women with CKD, elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are common. These hormonal changes are detected in the early stages of kidney disease and progressively worsen as kidney disease progresse .

. Women with chronic renal failure commonly have elevated circulating prolactin levels. As in men with chronic renal failure, the hypersecretion of prolactin in this setting appears to be autonomous, as it is resistant to maneuvers designed to stimulate or inhibit its release.

It has been suggested that the elevated prolactin levels may impair hypothalamic-pituitary function and contribute to sexual dysfunction and galactorrhea in these patients. However, uremic women treated with bromocryptine rarely resume normal menses and continue to complain of galactorrhea (if present), despite normalization of the plasma prolactin concentration. Thus, factors other than hyperprolactinemia must be important in this setting .

• Study Type: Observational
• Enrollment (Anticipated): 100

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

The Female Sexual Function Index (FSFI) will be used to assess sexual function .This index includes 19 questions related to 6 parameters: sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction and dyspareunia. A face-to-face inter-view with each participant in which the FSFI questions will be verbally asked and answered and compare between them in effect of renal failure on sexuality.

Duration of chronic renal failure duration of dialysis ,number of sessions of dialysis per week,medical treatment, haemoglobin and creatinine level will be fullfilled.

Description

Inclusion Criteria:

• -Female patients with chronic renal failure (eGFR <15 ml/min/1.7m2 ) on dialysis or not.
• Age from 18 to 45 years old.
• Married.
• Sexually active during the last 6 monthes.

Exclusion Criteria:

• Pregnant women.
• Other medical diseases ( diabetes mellitus ,cardiac disorders ,neurological disorders and other systematic diseases).
• Taking medications affect sexuality function e.g. antidepressant drugs.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Group A; 50 female end stage renal disease patients
Group B; 50 normal female patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
effect of chronic renal failure in females on their sexuality function	compare sexuality function between female with chronic renal failure and normal female and observe difference between two groups	two years

Collaborators and Investigators

• Sponsor: Esraa Ahmed Mohamed

Study record dates

Study Major Dates

• Study Start (Anticipated): July 1, 2017
• Primary Completion (Anticipated): July 31, 2018
• Study Completion (Anticipated): December 31, 2018

Study Registration Dates

• First Submitted: May 30, 2017
• First Submitted That Met QC Criteria: May 30, 2017
• First Posted (Actual): June 1, 2017

Study Record Updates

• Last Update Posted (Actual): June 1, 2017
• Last Update Submitted That Met QC Criteria: May 30, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Renal Insufficiency
• Other Study ID Numbers: FSDRF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No